Profile data is unavailable for this security.
About the company
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
- Revenue in USD (TTM)0.00
- Net income in USD-112.46m
- Incorporated2015
- Employees168.00
- LocationVor Biopharma Inc100 Cambridgepark Drive, Suite 101CAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 655-6580
- Fax+1 (302) 655-5049
- Websitehttps://www.vorbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precision BioSciences Inc | 75.10m | 11.48m | 49.86m | 108.00 | 8.51 | 0.7496 | 3.17 | 0.664 | 0.7641 | 0.0524 | 12.85 | 8.67 | 0.4729 | -- | 29.70 | 688,954.10 | 7.23 | -35.35 | 9.00 | -44.22 | -- | -- | 15.28 | -147.50 | -- | -- | 0.2557 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| Enzo Biochem Inc | 31.91m | -9.82m | 50.68m | 125.00 | -- | 0.9031 | -- | 1.59 | -0.194 | -0.5102 | 0.6268 | 1.07 | 0.3073 | 2.34 | 7.25 | 255,256.00 | -9.46 | -14.58 | -13.74 | -19.56 | 45.86 | 40.43 | -30.77 | -26.20 | 2.55 | -- | 0.0047 | -- | 2.72 | -17.03 | 60.77 | -- | -41.75 | -- |
| Nuo Therapeutics Inc | 1.17m | -2.48m | 50.79m | -- | -- | 57.04 | -- | 43.51 | -0.0561 | -0.0561 | 0.0264 | 0.0191 | 0.7034 | 1.37 | 4.15 | -- | -149.45 | -116.16 | -258.39 | -354.84 | 77.92 | 70.02 | -212.47 | -854.53 | 1.65 | -2,988.80 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
| Kronos Bio Inc | 9.86m | -85.59m | 52.72m | 58.00 | -- | 0.4747 | -- | 5.34 | -1.44 | -1.44 | 0.1656 | 1.84 | 0.0508 | -- | -- | 159,096.80 | -44.11 | -35.47 | -49.33 | -37.14 | -- | -- | -867.66 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| Prelude Therapeutics Inc | 3.00m | -131.52m | 53.23m | 128.00 | -- | 0.2608 | -- | 17.74 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Prenetics Global Ltd | 22.50m | -45.63m | 54.00m | 320.00 | -- | 0.2497 | -- | 2.40 | -3.79 | -4.14 | 1.86 | 17.70 | 0.0875 | 3.23 | 4.63 | 70,304.00 | -18.52 | -- | -22.89 | -- | 52.31 | -- | -211.67 | -- | 1.98 | -8.67 | 0.0122 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -25.94m | 54.46m | 13.00 | -- | 31.84 | -- | -- | -1.38 | -1.38 | 0.00 | 0.0675 | 0.00 | -- | -- | 0.00 | -319.37 | -- | -611.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -112.46m | 54.67m | 168.00 | -- | 0.7493 | -- | -- | -1.65 | -1.65 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -66.35 | -45.79 | -72.73 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 24.12m | -21.25m | 54.71m | 81.00 | -- | 0.4952 | -- | 2.27 | -0.3869 | -0.3869 | 0.436 | 2.00 | 0.1826 | -- | -- | 297,728.40 | -16.09 | -66.24 | -17.73 | -71.36 | -- | -- | -88.10 | -- | -- | -- | 0.0029 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Angion Biomedica Corp | 0.00 | -46.84m | 55.17m | 32.00 | -- | -- | -- | -- | -4.95 | -4.95 | 0.00 | -1.76 | 0.00 | -- | -- | 0.00 | -135.04 | -105.91 | -191.71 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 23.36 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| BioVie Inc | 0.00 | -26.77m | 55.23m | 14.00 | -- | 1.76 | -- | -- | -5.71 | -5.71 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -113.61 | -330.64 | -204.92 | -875.72 | -- | -- | -- | -- | -- | -186.65 | 0.191 | -- | -- | -- | 34.32 | -- | -- | -- |
| Aileron Therapeutics Inc | 0.00 | -29.24m | 55.90m | 15.00 | -- | 1.11 | -- | -- | -3.11 | -3.11 | 0.00 | 4.40 | 0.00 | -- | -- | 0.00 | -49.97 | -65.99 | -53.28 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -61.06m | 57.31m | 72.00 | -- | 0.3465 | -- | -- | -2.75 | -2.75 | 0.00 | 7.42 | 0.00 | -- | -- | 0.00 | -38.30 | -- | -40.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -153.78m | 57.42m | 109.00 | -- | 0.3297 | -- | -- | -9.14 | -9.14 | 0.00 | 10.22 | 0.00 | -- | -- | 0.00 | -131.73 | -- | -168.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.24m | 57.87m | 31.00 | -- | 1.22 | -- | -- | -1.33 | -1.33 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -54.12 | -58.43 | -57.23 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Champions Oncology Inc | 51.66m | -3.40m | 58.05m | 210.00 | -- | -- | -- | 1.12 | -0.2541 | -0.2541 | 3.78 | -0.0244 | 1.88 | -- | 5.75 | 245,976.20 | -12.39 | -10.00 | -44.43 | -23.00 | 44.27 | 46.58 | -6.58 | -6.04 | -- | -- | 333.00 | -- | -6.90 | 13.13 | -36.38 | -- | 0.0479 | -- |
Data as of Nov 22 2024. Currency figures normalised to Vor Biopharma Inc's reporting currency: US Dollar USD
55.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 22.75m | 33.26% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 6.98m | 10.21% |
| Hudson Bay Capital Management LPas of 30 Sep 2024 | 2.47m | 3.61% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.94m | 2.84% |
| TD Securities (USA) LLCas of 30 Sep 2024 | 1.22m | 1.79% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 756.01k | 1.11% |
| Sarissa Capital Management LPas of 30 Sep 2024 | 618.00k | 0.90% |
| MAI Capital Management LLCas of 30 Sep 2024 | 475.89k | 0.70% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 474.25k | 0.69% |
| Geode Capital Management LLCas of 30 Sep 2024 | 422.14k | 0.62% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
